Devyser Diagnostics

Devyser Diagnostics Current Assets

The Current Assets of Devyser Diagnostics (DVYSR.ST) as of Oct 22, 2026 is 137.30 M SEK. In the previous year, Current Assets was 242.20 M SEK — a change of -43.31% (lower).

Current Assets

137.30 MSEK

YoY

-43.31%

Last updated:

Current Assets of Devyser Diagnostics is 2025 137.30 M SEK. Current Assets of Devyser Diagnostics was 2024 242.20 M SEK. It decreases by -43.31% lower compared to the previous year.

The Devyser Diagnostics Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
27.84 M SEK
Jan 1, 2019
32.44 M SEK
Jan 1, 2020
39.69 M SEK
Jan 1, 2021
412.66 M SEK
Jan 1, 2022
445.58 M SEK
Jan 1, 2023
387.10 M SEK
Jan 1, 2024
242.20 M SEK
Jan 1, 2025
137.30 M SEK
The Devyser Diagnostics Current Assets history
YEARCurrent AssetsYoY
137.30 MSEK-43.31%
242.20 MSEK-37.43%
387.10 MSEK-13.12%
445.58 MSEK+7.98%
412.66 MSEK+939.68%
39.69 MSEK+22.36%
32.44 MSEK+16.51%
27.84 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Devyser Diagnostics Stock analysis

What does Devyser Diagnostics do? Devyser Diagnostics AB develops and sells genetic testing kits for routine diagnostics, targeting hereditary diseases, oncology, and post-transplantation monitoring. The company offers products like Devyser Thrombophilia assay and Devyser Resolution XY, which analyze DNA for diagnosing genetic conditions and guiding cancer treatment. These kits are sold directly to end customers or through hired distributors across more than 45 countries, with nearly 30 products developed since inception. The firm generates revenue through direct sales and distributor partnerships, focusing on healthcare providers and laboratories that require genetic testing solutions. Its products are used in complex DNA analysis for diagnosing hereditary disorders and optimizing cancer therapies, serving a global market in over 45 countries without relying on third-party brands or external partnerships beyond its own product portfolio. Devyser Diagnostics AB's business model centers on selling its proprietary genetic testing kits, with no mention of additional services or third-party collaborations. The company's revenue streams are derived solely from product sales, targeting healthcare institutions that utilize DNA testing for diagnostic and therapeutic purposes in specialized medical fields. Devyser Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Devyser Diagnostics stock

Current Assets of Devyser Diagnostics is 137.30 M SEK in 2025.

Current Assets of Devyser Diagnostics changed from 242.20 M SEK to 137.30 M SEK, representing a -43.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Devyser Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Devyser Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Devyser Diagnostics

All Key Metrics — Devyser Diagnostics